Detection of antineutrophil cytoplasmic antibody in primary sclerosing cholangitis: Comparison of the alkaline phosphatase and immunofluorescent techniques.

Detection of antineutrophil cytoplasmic antibody in primary sclerosing cholangitis: Comparison of the alkaline phosphatase and immunofluorescent techniques.

Pokaži ostale verzije (1)

Bibliografski detalji
Glavni autori:	Bansi, D, Boberg, K, Broome, U, Chapman, R, Fleming, K, Jorgensen, R, Lindor, K, Schrumpf, E
Format:	Journal article
Izdano:	1996

Slični predmeti

DETECTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY IN PRIMARY SCLEROSING CHOLANGITIS - COMPARISON OF THE ALKALINE-PHOSPHATASE AND IMMUNOFLUORESCENT TECHNIQUES
od: Bansi, D, i dr.
Izdano: (1995)

Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques.
od: Bansi, D, i dr.
Izdano: (1997)

Characterisation of the antigen for the antineutrophil cytoplasmic antibody specific for primary sclerosing cholangitis
od: Cameron, B, i dr.
Izdano: (1998)

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES AFTER LIVER-TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS
od: Bansi, D, i dr.
Izdano: (1995)

IGG SUBCLASS DISTRIBUTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN PRIMARY SCLEROSING CHOLANGITIS AND ULCERATIVE-COLITIS
od: Bansi, D, i dr.
Izdano: (1995)

Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis.
od: Bansi, D, i dr.
Izdano: (1996)

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES ARE ABSENT IN UNAFFECTED RELATIVES OF PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND ULCERATIVE-COLITIS
od: Bansi, D, i dr.
Izdano: (1995)

Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.
od: Bansi, D, i dr.
Izdano: (1996)

Characterization of the antigen for the antineutrophil cytoplasmic antibody specific for primary sclerosing cholangitis (PSC) ulcerative colitis (UC).
od: Cameron, B, i dr.
Izdano: (1998)

ANTINEUTROPHIL ANTIBODY AND PRIMARY SCLEROSING CHOLANGITIS
od: Lo, S, i dr.
Izdano: (1991)

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY TITER BUT NOT IGG SUBCLASS DISTINGUISHES BETWEEN PRIMARY SCLEROSING CHOLANGITIS AND AUTOIMMUNE HEPATITIS
od: Bans, D, i dr.
Izdano: (1995)

Antineutrophil cytoplasmic antibodies in autoimmune hepatitis.
od: Bansi, D, i dr.
Izdano: (1995)

Antigen specificity of antineutrophil antibodies in ulcerative colitis, primary sclerosing cholangitis and autoimmune hepatitis
od: Bansi, D, i dr.
Izdano: (1996)

Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique.
od: Lo, S, i dr.
Izdano: (1992)

Patients with small duct primary sclerosing cholangitis have favorable long term prognosis.
od: Bjornsson, E, i dr.
Izdano: (2001)

Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood?
od: Lo, S, i dr.
Izdano: (1993)

Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
od: Bansi, D, i dr.
Izdano: (1996)

Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 European primary sclerosing cholangitis patients
od: Boberg, K, i dr.
Izdano: (2000)

Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis
od: Moira Hilscher, i dr.
Izdano: (2016-03-01)

Cholangiocarcinoma in primary sclerosing cholangitis is associated with long-standing inflammatory bowel disease. A long-term follow-up of 394 primary sclerosing cholangitis patients.
od: Boberg, K, i dr.
Izdano: (2001)

The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis.
od: Talwalkar, J, i dr.
Izdano: (2013)

Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass.
od: Bansi, D, i dr.
Izdano: (1996)

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.
od: Boberg, K, i dr.
Izdano: (2002)

Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.
od: Björnsson, E, i dr.
Izdano: (2002)

Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis
od: Juliana Goldbaum Crescente, i dr.

New time dependent prognostic models for primary sclerosing cholangitis (PSC)
od: Rocca, G, i dr.
Izdano: (2000)

The immunogenetic basis for anti-neutrophil cytoplasmic antibody production in primary sclerosing cholangitis and ulcerative colitis.
od: Mehal, W, i dr.
Izdano: (1994)

HLA class II haplotypes in primary sclerosing cholangitis patients from five ethnic groups.
od: Saarinen, S, i dr.
Izdano: (1998)

Prognostic indicators of primary sclerosing cholangitis determined by a cox phase-specific time-dependent model.
od: Boberg, K, i dr.
Izdano: (1998)

Antigen specificity of antineutrophil antibodies in ulcerative colitis, primary sclerosing and autoimmune hepatitis.
od: Bansi, D, i dr.
Izdano: (1996)

Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis.
od: Boberg, K, i dr.
Izdano: (2002)

Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.
od: Mitchell, SA, i dr.
Izdano: (2001)

Diagnosis and management of primary sclerosing cholangitis.
od: Chapman, R, i dr.
Izdano: (2010)

Primary sclerosing cholangitis
od: Marina G Silveira, i dr.
Izdano: (2008-01-01)

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
od: Mitchell, SA, i dr.
Izdano: (2001)

Is the 308 polymorphism in the tumor necrosis factor (alpha) (TNF alpha) promoter region a marker of disease susceptibility in European patients with primary sclerosing cholangitis (PSC)?
od: Mitchell, SA, i dr.
Izdano: (1998)

The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis.
od: Boberg, K, i dr.
Izdano: (2001)

Primary sclerosing cholangitis.
od: Williamson, K, i dr.
Izdano: (2014)

High-dose ursodeoxycholic acid in primary sclerosing cholangitis a randomised double-blind placebo-controlled trial
od: Bansi, D, i dr.
Izdano: (1996)

INTERFERON-GAMMA PRODUCTION IN PRIMARY SCLEROSING CHOLANGITIS
od: Martins, E, i dr.
Izdano: (1995)